Compagnie Lombard Odier S Cm A Apellis Pharmaceuticals, Inc. Transaction History
Compagnie Lombard Odier S Cm A
- $8.71 Billion
- Q3 2025
A detailed history of Compagnie Lombard Odier S Cm A transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Compagnie Lombard Odier S Cm A holds 11,000 shares of APLS stock, worth $216,810. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,000
Previous 11,000
-0.0%
Holding current value
$216,810
Previous $190,000
30.53%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding APLS
# of Institutions
303Shares Held
135MCall Options Held
2.97MPut Options Held
623K-
Avoro Capital Advisors LLC New York, NY12.2MShares$241 Million3.86% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$234 Million17.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.2MShares$200 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.75MShares$192 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.98MShares$177 Million0.03% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.17B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...